Serina Therapeutics, Inc. SER
Set alert
1.85 USD -0.09 -4.64%
At close · Nov 2
2.09 +0.24 +13.12%
After hours · Nov 2, 4:00 PM ET
1.85 Day range 1.99
1.22 52-week range 4.99
- YTD
- -3.14%
- 1 year
- -63.00%
- Open
- 1.92
- Prev close
- 1.94
- Mkt cap
- 46.99M
- Vol
- 38.99K
- Avg vol
- 70.02K
- EPS
- -1.87
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.85
- High
- 1.99
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 1.96
- Inst. own
- 3.37%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.80
- 200-d avg
- 8.47
- 1y target
- 0.00
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 20 hours ago |
| SMA: Bullish | Oct 30, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 27, 2026 | 6 days ago |
| RSI: Oversold | Oct 19, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
Financial health
Altman Z-Score
-3.66 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 4
Valuation
P/E -1.0×
FY 2016 5y median -3.3× FY 2025
P/S 0.0×
FY 2016 5y median 36.7× FY 2025
P/B -526×
FY 2016 5y median -3.5× FY 2025
P/FCF -1.1×
FY 2016 5y median -10.2× FY 2025
EV/EBITDA -0.9×
FY 2016 5y median -3.2× FY 2025
EV/Sales 0.0×
FY 2016 5y median 35.4× FY 2025
FCF Yield -92.3%
FY 2016 5y median -9.8% FY 2025
Profitability
Gross Margin 0.0%
FY 2016 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2016 5y median -99.2% FY 2025
Net Margin 0.0%
FY 2016 5y median -36.5% FY 2025
ROE 51843.2%
FY 2016 5y median 10.7% FY 2025
ROIC -709.0%
FY 2016 5y median -280.6% FY 2025
ROA -276.0%
FY 2016 5y median -82.8% FY 2025
Growth (YoY)
Revenue -100.0%
FY 2016 FY 2025
Operating Income -40.9%
FY 2016 FY 2025
EPS (diluted) -26.5%
FY 2016 FY 2025
Free Cash Flow -4.6%
FY 2016 FY 2025
Financial Health
Current Ratio 1.7×
FY 2016 5y median 1.7× FY 2025
Quick Ratio 1.7×
FY 2016 5y median 1.7× FY 2025
Debt / Equity -5.3×
FY 2016 5y median -1.1× FY 2025
Net Debt / EBITDA 0.2×
FY 2016 5y median -0.7× FY 2025
Interest Coverage -113×
FY 2016 5y median -113× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
